Bloomberg(@business):Drugmakers were expecting big things when generic Ozempic hit Indian pharmacies. But it didn’t happen. In March, Indian patents on the active ingredient in weight-loss drugs Ozempic and Wegovy expired, unleashing a flood of cheaper copycat versions in the country. The medical community is now realizing that cost is just one of many barriers, particularly in India, to the adoption of weight-loss medications. Read the full Businessweek story here: https://t.co/84b5ByO7nM 🎨: Hitesh Sonar for Bloomberg Businessweek; 📷️: Getty Images (2)

2026.10.01 13:30

Drugmakers were expecting big things when generic Ozempic hit Indian pharmacies. But it didn’t happen. In March, Indian patents on the active ingredient in weight-loss drugs Ozempic and Wegovy expired, unleashing a flood of cheaper copycat versions in the country. The medical community is now realizing that cost is just one of many barriers, particularly in India, to the adoption of weight-loss medications. Read the full Businessweek story here: 🎨: Hitesh Sonar for Bloomberg Businessweek; 📷️: Getty Images (2)